Imunon Q1 net loss $4.9M ($0.52/shr), appoints Stacy Lindborg as CEO; OVATION 2 data expected mid-2024

Imunon, Inc.

2024-Q1 EPS reported -$0.52

Net loss of $4.9M ($0.52/shr) vs $5.6M ($0.68/shr) in Q1 2023; operating expenses down 12% to $5.0M.
Cash and investments $9.8M; believes funding sufficient through end of 2024.
Stacy Lindborg appointed President and CEO effective May 13, 2024; previously a director and Co-CEO of BrainStorm.
OVATION 2 Study of IMNN-001 in advanced ovarian cancer: interim PFS delay ~3 months, OS improvement ~9 months; final readout mid-2024.
FDA cleared IND for IMNN-101 seasonal COVID booster; Phase 1 starting Q2 2024. Received $1.3M non-dilutive from NJ NOL sale.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Imunon, Inc. reported financial results for quarter ended March 31, 2024.

Period: quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Imunon, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018791

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.